Journal profile · Immunology
Expert Review of Vaccines
ISSN 1476-0584 · eISSN 1744-8395 · Taylor and Francis Ltd. · ENGLAND · Bimonthly · Founded 2002
Expert Review of Vaccines: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.57; JCR Q1 (journal website); fully open access; APC about USD 4,450; median 122 days to acceptance (95 articles, last 24 months); community-reported acceptance: moderate; 107 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Vaccines is published by Taylor and Francis Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, Influenza Virus Research Studies and Vaccine Coverage and Hesitancy, together about 26.8% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
*Please note that Expert Review of Vaccines converted to a full Open Access journal from Volume 22 (2023). Previous volumes will continue to provide access through a Pay to Read model. Expert Review of Vaccines (e-ISSN 1744-8395) is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed research in the development, application, and clinical effectiveness of new vaccines. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field. The journal features cutting edge reviews and original articles on vaccines, the immune response, and the powerful impact of immunization against infectious diseases. We also cover vaccine technologies and platforms, adjuvants, therapeutic vaccines and vaccination for the control of non-communicable diseases. Alongside review articles, the journal welcomes clinically relevant and novel original research. Pharmacoeconomic studies are considered if there is clear clinical relevance. Please note that the journal does not publish case reports, case series or animal studies. Letters to the Editor should discuss articles previously published in the journal. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Vaccines, part of the Expert Collection brand. For any pre-submission enquiries, please contact the Commissioning Editor. Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editor-in-chief Andrew J PollardPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 17, United Kingdom 4, Australia 4, Japan 2, South Korea 2 (48 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology9.3%
- Influenza Virus Research StudiesMedicine8.9%
- Vaccine Coverage and HesitancySocial Sciences8.7%
- Respiratory viral infections researchMedicine7.1%
- Pneumonia and Respiratory InfectionsMedicine6.9%
- vaccines and immunoinformatics approachesBiochemistry, Genetics and Molecular Biology6.6%
- SARS-CoV-2 and COVID-19 ResearchMedicine6.4%
- Viral gastroenteritis research and epidemiologyMedicine5.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Index Medicus, Biobase, Journal Citation Reports/Science Edition®
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.57LetPub ·
- Impact factor (publisher) 2025
- 5.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.6Publisher website ·
- CiteScore 2026-06
- 9.9LetPub ·
- CiteScore (publisher) 2025
- 9.9Publisher website ·
- SJR 2026-06
- 1.28LetPub ·
- SJR (publisher) 2025
- 1.28Publisher website ·
- SNIP 2026-06
- 1.3LetPub ·
- SNIP (publisher) 2025
- 1.3Publisher website ·
- h-index
- 75LetPub ·
- h-index
- 131OpenAlex ·
- i10-index
- 2,015OpenAlex ·
- 2-year mean citedness
- 5.35OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 99.25%LetPub ·
Volume
- Articles per year
- 97LetPub ·
- Downloads per year (publisher)
- 845,000Publisher website ·
Articles by year OpenAlex count · 3,131 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 84 | 84 | 31 |
| 2025 | 107 | 107 | 473 |
| 2024 | 83 | 83 | 962 |
| 2023 | 108 | 108 | 1,629 |
| 2022 | 137 | 87 | 2,593 |
| 2021 | 190 | 111 | 5,717 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
122 daysMedian, submission to acceptance · P25–P75 72 days – 188 days
- Acceptance to online
- median 11 days (95 articles)
- Submission to online
- median 139 days
- Sample
- 95 articles with submission and acceptance dates (214 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Acceptance rate (publisher)
- 39%Publisher website ·
- Submission to first decision
- 32 daysPublisher website ·
- First decision after review
- 56 daysPublisher website ·
- Acceptance to publication
- 10 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | AUD 6,075 / EUR 4,060 / GBP 3,495 / USD 4,450 | Yes | CC BY, CC BY-NC | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- letters to the editorLetters to the Editor should discuss articles previously published in the journal.Length not stated
- original researchAlongside review articles, the journal welcomes clinically relevant and novel original research.Length not stated
- review articlesThe journal features cutting edge reviews and original articles on vaccines, the immune response, and the powerful impact of immunization against infectious dis…Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Expert Review of Vaccines is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just tho…
Source ↗Publisher website ·- Peer review
Does not publish case reports, case series or animal studies Model summary
Please note that the journal does not publish case reports, case series or animal studies.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2002
- ISSN
- 1476-0584
- Electronic ISSN
- 1744-8395
- Latest issue on the website
- Volume 25, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Expert Review of Vaccines
What CAS zone is Expert Review of Vaccines in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Vaccines is in Zone 2 of Medicine, and in Zone 3 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Vaccines?
The latest impact factor listed by LetPub is 5.57; CiteScore 9.9, h-index 131.
How long does peer review take at Expert Review of Vaccines?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 72–188 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate”; the journal's website gives an acceptance rate of 39%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Expert Review of Vaccines in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Where are the editorial board members of Expert Review of Vaccines based?
Of the 48 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (17), United Kingdom (4) and Australia (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Expert Review of Vaccines?
According to LetPub and DOAJ records, Expert Review of Vaccines is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Expert Review of Vaccines open access, and what is the APC?
Expert Review of Vaccines is a fully open-access journal. APC about USD 4,450.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .